Literature DB >> 25136009

In vivo efficacy of apramycin in murine infection models.

Martin Meyer1, Pietro Freihofer1, Michael Scherman2, Joanne Teague3, Anne Lenaerts2, Erik C Böttger4.   

Abstract

Apramycin is a unique aminoglycoside with a dissociation of antibacterial activity and ototoxicity. We assessed the antibacterial efficacy of apramycin in two murine models of infection, Mycobacterium tuberculosis aerosol infection and Staphylococcus aureus septicemia. In both infection models, the efficacy of apramycin was comparable to that of amikacin. These results suggest that apramycin has the potential to become a clinically useful agent against drug-resistant pathogens and support further development of this promising unique aminoglycoside.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25136009      PMCID： PMC4249428          DOI： 10.1128/AAC.03239-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  24 in total

1.  Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates.

Authors:  D M Livermore; S Mushtaq; M Warner; J-C Zhang; S Maharjan; M Doumith; N Woodford
Journal:  J Antimicrob Chemother       Date:  2010-11-14       Impact factor: 5.790

Review 2.  Drugs for bad bugs: confronting the challenges of antibacterial discovery.

Authors:  David J Payne; Michael N Gwynn; David J Holmes; David L Pompliano
Journal:  Nat Rev Drug Discov       Date:  2006-12-08       Impact factor: 84.694

Review 3.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

Authors:  David E Griffith; Timothy Aksamit; Barbara A Brown-Elliott; Antonino Catanzaro; Charles Daley; Fred Gordin; Steven M Holland; Robert Horsburgh; Gwen Huitt; Michael F Iademarco; Michael Iseman; Kenneth Olivier; Stephen Ruoss; C Fordham von Reyn; Richard J Wallace; Kevin Winthrop
Journal:  Am J Respir Crit Care Med       Date:  2007-02-15       Impact factor: 21.405

4.  Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice.

Authors:  Ann Sturdy; Anna Goodman; Ricardo J José; Angela Loyse; Marie O'Donoghue; Onn Min Kon; Martin J Dedicoat; Thomas S Harrison; Laurence John; Marc Lipman; Graham S Cooke
Journal:  J Antimicrob Chemother       Date:  2011-06-03       Impact factor: 5.790

5.  Introducing mutations into a chromosomal rRNA gene using a genetically modified eubacterial host with a single rRNA operon.

Authors:  P Sander; T Prammananan; E C Böttger
Journal:  Mol Microbiol       Date:  1996-12       Impact factor: 3.501

6.  A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae.

Authors:  T Prammananan; P Sander; B A Brown; K Frischkorn; G O Onyi; Y Zhang; E C Böttger; R J Wallace
Journal:  J Infect Dis       Date:  1998-06       Impact factor: 5.226

7.  The in vitro activity of apramycin, a new aminocyclitol antibiotic.

Authors:  R Ryden; B J Moore
Journal:  J Antimicrob Chemother       Date:  1977-11       Impact factor: 5.790

8.  Plasmid-mediated high-level resistance to aminoglycosides in Enterobacteriaceae due to 16S rRNA methylation.

Authors:  Marc Galimand; Patrice Courvalin; Thierry Lambert
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

Review 9.  Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis.

Authors:  Scott G Franzblau; Mary Ann DeGroote; Sang Hyun Cho; Koen Andries; Eric Nuermberger; Ian M Orme; Khisimuzi Mdluli; Iñigo Angulo-Barturen; Thomas Dick; Veronique Dartois; Anne J Lenaerts
Journal:  Tuberculosis (Edinb)       Date:  2012-08-30       Impact factor: 3.131

10.  4'-O-substitutions determine selectivity of aminoglycoside antibiotics.

Authors:  Déborah Perez-Fernandez; Dmitri Shcherbakov; Tanja Matt; Ng Chyan Leong; Iwona Kudyba; Stefan Duscha; Heithem Boukari; Rashmi Patak; Srinivas Reddy Dubbaka; Kathrin Lang; Martin Meyer; Rashid Akbergenov; Pietro Freihofer; Swapna Vaddi; Pia Thommes; V Ramakrishnan; Andrea Vasella; Erik C Böttger
Journal:  Nat Commun       Date:  2014       Impact factor: 14.919
View more
  10 in total

1.  System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis.

Authors:  Xingji Zheng; Yossef Av-Gay
Journal:  J Vis Exp       Date:  2017-04-05       Impact factor: 1.355

2.  Evaluation of apramycin against spectinomycin-resistant and -susceptible strains of Neisseria gonorrhoeae.

Authors:  Stefan Riedel; Divya Vijayakumar; Gretchen Berg; Anthony D Kang; Kenneth P Smith; James E Kirby
Journal:  J Antimicrob Chemother       Date:  2019-05-01       Impact factor: 5.790

3.  Structure-Based Design and Synthesis of Apramycin-Paromomycin Analogues: Importance of the Configuration at the 6'-Position and Differences between the 6'-Amino and Hydroxy Series.

Authors:  Appi Reddy Mandhapati; Guanyu Yang; Takayuki Kato; Dimitri Shcherbakov; Sven N Hobbie; Andrea Vasella; Erik C Böttger; David Crich
Journal:  J Am Chem Soc       Date:  2017-10-09       Impact factor: 15.419

4.  Efficacy of Apramycin against Multidrug-Resistant Acinetobacter baumannii in the Murine Neutropenic Thigh Model.

Authors:  Anthony D Kang; Kenneth P Smith; Anders H Berg; Katherine A Truelson; George M Eliopoulos; Christopher McCoy; James E Kirby
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

5.  Apralogs: Apramycin 5-O-Glycosides and Ethers with Improved Antibacterial Activity and Ribosomal Selectivity and Reduced Susceptibility to the Aminoacyltranserferase (3)-IV Resistance Determinant.

Authors:  Jonathan C K Quirke; Parasuraman Rajasekaran; Vikram A Sarpe; Amr Sonousi; Ivan Osinnii; Marina Gysin; Klara Haldimann; Qiao-Jun Fang; Dimitri Shcherbakov; Sven N Hobbie; Su-Hua Sha; Jochen Schacht; Andrea Vasella; Erik C Böttger; David Crich
Journal:  J Am Chem Soc       Date:  2019-12-17       Impact factor: 15.419

6.  Evaluation of apramycin activity against methicillin-resistant, methicillin-sensitive, and vancomycin-intermediate Staphylococcus aureus clinical isolates.

Authors:  Katherine A Truelson; Thea Brennan-Krohn; Kenneth P Smith; James E Kirby
Journal:  Diagn Microbiol Infect Dis       Date:  2018-05-29       Impact factor: 2.803

7.  Pharmacokinetics and relative bioavailability of an oral amoxicillin-apramycin combination in pigs.

Authors:  Chongshan Dai; Tingting Zhao; Xing Yang; Xilong Xiao; Tony Velkov; Shusheng Tang
Journal:  PLoS One       Date:  2017-04-20       Impact factor: 3.240

8.  Repurposing the Veterinary Antibiotic Apramycin for Antibacterial and Antibiofilm Activity Against Pseudomonas aeruginosa From Cystic Fibrosis Patients.

Authors:  Giovanni Di Bonaventura; Veronica Lupetti; Fabio Verginelli; Sara Giancristofaro; Rosemary Barbieri; Giovanni Gherardi; Arianna Pompilio
Journal:  Front Microbiol       Date:  2022-02-03       Impact factor: 5.640

9.  Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose.

Authors:  Chenyan Zhao; Anna Chirkova; Staffan Rosenborg; Rodrigo Palma Villar; Johan Lindberg; Sven N Hobbie; Lena E Friberg
Journal:  J Antimicrob Chemother       Date:  2022-09-30       Impact factor: 5.758

10.  In vitro and in vivo Evaluation of Synergism between Anti-Tubercular Spectinamides and Non-Classical Tuberculosis Antibiotics.

Authors:  David F Bruhn; Michael S Scherman; Jiuyu Liu; Dimitri Scherbakov; Bernd Meibohm; Erik C Böttger; Anne J Lenaerts; Richard E Lee
Journal:  Sci Rep       Date:  2015-09-14       Impact factor: 4.379
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.